tiprankstipranks
Philogen SpA (DE:78Q)
STUTTGART:78Q
Holding DE:78Q?
Track your performance easily

Philogen SpA (78Q) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

78Q Analyst Ratings

Moderate Buy
1Ratings
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Philogen
SpA
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

78Q Stock 12 Month Forecast

Average Price Target

€25.00
▲(27.55% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Philogen SpA in the last 3 months. The average price target is €25.00 with a high forecast of €25.00 and a low forecast of €25.00. The average price target represents a 27.55% change from the last price of €19.60.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"€15","26":"€26","17.75":"€17.75","20.5":"€20.5","23.25":"€23.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,17.75,20.5,23.25,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.8,20.2,20.6,21,21.400000000000002,21.8,22.2,22.6,23,23.4,23.8,24.2,24.6,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.8,20.2,20.6,21,21.400000000000002,21.8,22.2,22.6,23,23.4,23.8,24.2,24.6,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.8,20.2,20.6,21,21.400000000000002,21.8,22.2,22.6,23,23.4,23.8,24.2,24.6,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.9,"date":1700179200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.05,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.75,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.95,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.2,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.4,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.4,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.4,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€25.00Average Price Target€25.00Lowest Price Target€25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs
Buy
Reiterated
04/04/24
Philogen S.p.A. (PHIL.MI): FY23 update: Nidlegy filing in melanoma on track for 1H24; reiterate 2024 | 12:06PM BST Philogen reported FY23 results and held a follow-up investor call to provide updates from across the pipeline where, most importantly to us, the company reports that it is finalising submission documents ahead of an anticipated regulatory filing to the EMA in 1H24 for lead asset Nidlegy in melanoma, following positive topline data reported in October 2023. Preparations for commercialisation are underway with partner Sun Pharma, while presentation of full Phase 3 data at a medical conference is expected during 2024. We next look for incremental details on the filing strategy for Nidlegy ex-EU, including potential updates on interactions with the US FDA.

Best Analysts Covering Philogen SpA

Which Analyst Should I Follow If I Want to Buy DE:78Q and Sell After:
1 Month
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+5.33%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +5.33% per trade.
3 Months
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+10.20%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +10.20% per trade.
1 Year
Rajan SharmaGoldman Sachs
Success Rate
3/3 ratings generated profit
100%
Average Return
+14.67%
reiterated a buy rating 8 months ago
Copying Rajan Sharma's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +14.67% per trade.
2 Years
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+14.57%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +14.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

78Q Analyst Recommendation Trends

Rating
May 24
Jun 24
Jul 24
Oct 24
Nov 24
Strong Buy
0
0
0
0
0
Buy
4
4
3
3
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
4
3
3
3
In the current month, 78Q has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 78Q average Analyst price target in the past 3 months is €25.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

78Q Financial Forecast

78Q Earnings Forecast

Next quarter’s earnings estimate for 78Q is €6.15 with a range of €6.15 to €6.15. The previous quarter’s EPS was ―. 78Q beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 59.62% of the time in the same period. In the last calendar year 78Q has Underperformed its overall industry.
Next quarter’s earnings estimate for 78Q is €6.15 with a range of €6.15 to €6.15. The previous quarter’s EPS was ―. 78Q beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 59.62% of the time in the same period. In the last calendar year 78Q has Underperformed its overall industry.

78Q Sales Forecast

Next quarter’s sales forecast for 78Q is €302.80M with a range of €302.80M to €302.80M. The previous quarter’s sales results were ―. 78Q beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 48.39% of the time in the same period. In the last calendar year 78Q has Underperformed its overall industry.
Next quarter’s sales forecast for 78Q is €302.80M with a range of €302.80M to €302.80M. The previous quarter’s sales results were ―. 78Q beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 48.39% of the time in the same period. In the last calendar year 78Q has Underperformed its overall industry.

78Q Stock Forecast FAQ

What is DE:78Q’s average 12-month price target, according to analysts?
Based on analyst ratings, Philogen SpA’s 12-month average price target is €25.00.
    What is DE:78Q’s upside potential, based on the analysts’ average price target?
    Philogen SpA has 27.55% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Philogen SpA a Buy, Sell or Hold?
          Philogen SpA has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Philogen SpA’s share price target?
            The average share price target for Philogen SpA is €25.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €25.00 ,and the lowest forecast is €25.00. The average share price target represents 27.55% Increase from the current price of €19.6.
              What do analysts say about Philogen SpA?
              Philogen SpA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Philogen SpA?
                To buy shares of DE:78Q, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis